<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862976</url>
  </required_header>
  <id_info>
    <org_study_id>371/18</org_study_id>
    <nct_id>NCT03862976</nct_id>
  </id_info>
  <brief_title>Antepartum Cardiotocography With and Without Computer Analysis in High Risk Pregnancies</brief_title>
  <official_title>Antepartum Cardiotocography With and Without Computer Analysis in High Risk Pregnancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electronic fetal hear rate monitoring (EFM), or cardiotocography (CTG), records changes in
      fetal heart rate and their temporal relationship to uterine contraction. It has been
      developed with the aim of detecting fetal hypoxia during labor and hence to prevent metabolic
      acidosis. Despite being the standard for intrapartum management, this technique,
      significantly increase the operative delivery rate, and is associated only with less seizures
      as neonatal benefit. Another concern is also the variability in the interpretation.

      Several techniques have been studied in order to decrease the high false positive rate. Fetal
      ST waveform analysis (STAN) has been studied combined with CTG. A recent meta-analysis of
      randomized trials, however, showed that STAN during labor did not improve perinatal outcomes
      or decrease operative delivery rates, except for a 9% decrease in operative vaginal
      delivery.Comparisons of visual and computerized interpretation of EFM have also been
      reported. However, whether or fetal monitoring with computer analysis improve perinatal
      outcomes is still subject of debate.

      Thus, we aim to evaluate whether intrapartum fetal monitoring with computer analysis increase
      the incidence of obstetric intervention when compared with visual analysis through a
      single-center randomized controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">March 23, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cesarean section</measure>
    <time_frame>at the time of delivery</time_frame>
    <description>incidence of cesarean section</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gestational age at delivery</measure>
    <time_frame>at the time of delivery</time_frame>
    <description>week of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>admission to neonatal intensive care unit</measure>
    <time_frame>at the time of delivery</time_frame>
    <description>admission to neonatal intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>birth weight</measure>
    <time_frame>at the time of delivery</time_frame>
    <description>neonatal birth weight at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score at delivery</measure>
    <time_frame>at the time of delivery</time_frame>
    <description>APGAR score at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal death</measure>
    <time_frame>28 days of live of the neonate</time_frame>
    <description>death of a live neonates within 28 days of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>computerized cardiotocography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>computerized cardiotocography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard cardiotocography</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard cardiotocography non stresstest</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>computerized cardiotocography</intervention_name>
    <description>computerized cardiotocography (C-CTG)</description>
    <arm_group_label>computerized cardiotocography</arm_group_label>
    <arm_group_label>standard cardiotocography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with singleton gestation

          -  18 years to 50 years

          -  High risk pregnancies: DM, or GDM, or hypertension, or preeclampsia

        Exclusion Criteria:

        - IUGR
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gabriele Saccone</name>
      <address>
        <city>Napoli</city>
        <zip>80129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Gabriele Saccone</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>not planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

